This episode currently has no reviews.
Submit ReviewIntel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review